Search the Site

Twitter

test tubes

$NGSX Pain Drug Developer Awaits 1Q12 FDA (sNDA) Decision

publication date: Jan 4, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Written by Mike Havrilla--NeurogesX (NASDAQ:NGSX) is focused on the development and marketing of treatments for pain. Below is a summary of the Company's currently approved pain drug skin patch which the Company markets in the US and is marketed by Astellas in Europe.


Sorry this page is available to subscribers only. If you're not a subscriber why not join today?

You can also sign up for our 100% FREE Newsletter  to stay current on public webinars, special offers, and news alerts:

FREE NEWSLETTER

If you are already a subscriber, please login.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site including:

- Detailed Reports on Upcoming FDA and Clinical Trial Trades
- REAL TIME Posting of Trades (Entries and Exits)
- Clinical and Regualtory Catalyst Database (updated daily)
- Members Only Live Interactive Webinars 
- Weekly Watchlist
- Email / SMS (Text Message) Alerts of critical news
- A More Detailed FDA Calendar
- Direct Email Communication
- Affiliate Program

If you believe you should be able to view this area then please contact us and we will try to rectify this issue as soon as possible.